Get the Stockscreener App
8.81
2.33%
-0.21
After Hours:
8.81
Alvotech stock is traded at $8.81, with a volume of 157.38K.
It is down -2.33% in the last 24 hours and down -17.35% over the past month.
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
See More
Previous Close:
$9.02
Open:
$8.93
24h Volume:
157.38K
Relative Volume:
0.83
Market Cap:
$3.21B
Revenue:
$391.87M
Net Income/Loss:
$-441.45M
P/E Ratio:
-4.7622
EPS:
-1.85
Net Cash Flow:
$-301.21M
1W Performance:
-2.87%
1M Performance:
-17.35%
6M Performance:
-33.51%
1Y Performance:
-27.49%
1-Day Range:
$8.81
$9.00
1-Week Range:
$8.81
$9.26
52-Week Range:
$7.35
$13.70
Alvotech Stock (ALVO) Company Profile
Compare ALVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
8.81 | 3.21B | 391.87M | -441.45M | -301.21M | -1.85 |
|
RGC
Regencell Bioscience Holdings Ltd
|
19.31 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
157.80 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.05 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.02 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.63 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-25 | Initiated | UBS | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Upgrade | Citigroup | Sell → Neutral |
| Sep-21-23 | Initiated | Barclays | Equal Weight |
| Sep-07-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-06-22 | Downgrade | Citigroup | Buy → Sell |
| Jul-26-22 | Initiated | Citigroup | Buy |
View All
Alvotech Stock (ALVO) Latest News
Day 8 of Loss Streak for Alvotech Stock with -15% Return (vs. -32% YTD) [6/18/2025] - Trefis
Alvotech and Dr. Reddy’s Partner to Develop Biosimilar of Merck’s Keytruda for Global Cancer Treatment - geneonline.com
Alvotech and Dr. Reddy’s Partner to Develop Biosimilar for Cancer Drug Pembrolizumab - geneonline.com
Short Interest in Alvotech (NASDAQ:ALVO) Grows By 75.2% - MarketBeat
Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan - Center for Biosimilars
Alvotech and Dr. Reddy’s Partner to Develop Biosimilar for Keytruda Cancer Drug - geneonline.com
Alvotech, Dr. Reddy’s to co-develop Keytruda biosimilar - Drug Store News
Alvotech (NASDAQ:ALVO) Trading Down 3.3%Should You Sell? - MarketBeat
Dr. Reddy’s shares rise over 1% on strategic collaboration with Alvotech for Keytruda Biosimilar - MSN
Millennium Management LLC Trims Position in Alvotech (NASDAQ:ALVO) - MarketBeat
Alvotech and Dr. Reddy’s partner to co-develop biosimilar candidate for Merck's Keytruda - MSN
Linklaters Advises Syndicate on Alvotech’s SEK 750 Million Private Placement - Global Legal Chronicle
Alvotech Completes Private Placement to Boost Shareholder Base - TipRanks
Alvotech and Dr. Reddy’s Partner to Develop Biosimilar for Pembrolizumab Used in Cancer Treatment - geneonline.com
Alvotech completes private placement with 40 institutional investors By Investing.com - Investing.com Australia
Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors - The Manila Times
Alvotech Completes Successful Private Placement with Global Institutional Investors - Nasdaq
Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors - Yahoo Finance
REG-Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors - TradingView
Alvotech Attracts 40 New Global Investors in Strategic Private Placement, 80% First-Time Buyers - Stock Titan
Alvotech at Goldman Sachs Conference: Strategic Growth in Biosimilars - Investing.com
Alvotech at Goldman Sachs Conference: Strategic Growth in Biosimilars By Investing.com - Investing.com South Africa
Transcript : Alvotech Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 08 - marketscreener.com
Alvotech Partners with Dr. Reddy’s for Keytruda Biosimilar Development - TipRanks
Wall Street Analysts Think Alvotech (ALVO) Could Surge 72.61%: Read This Before Placing a Bet - MSN
Alvotech, Advanz Pharma expand biosimilar deal in Europe - Drug Store News
Dr Reddy's, Alvotech join hands to develop biosimilar for cancer treatment - MSN
Dr Reddy’s–Alvotech deal: Why investors are bullish - MSN
Dr Reddys Lab gains on global biosimilar deal with Alvotech - MSN
Alvotech (NASDAQ:ALVO) Stock Price Down 4.8%What's Next? - MarketBeat
Alvotech and Dr. Reddy’s to co-develop biosimilar candidate to Keytruda® (pembrolizumab) - BioSpectrum Asia
Alvotech and Dr. Reddy’s Join Forces to Develop Biosimilar | - Chemical Industry Digest
Alvotech (ALVO) Partners with Dr. Reddy's for Keytruda Biosimila - GuruFocus
Dr Reddy's, Alvotech join hands to co-develop, manufacture & commercialise biosimilar of Merck's blockbuster drug Keytruda - MSN
Alvotech and Dr. Reddy’s partner for Keytruda biosimilar - Pharmaceutical Business review -
Dr Reddy's, Alvotech Partner To Develop Biosimilar For Cancer Treatment - MSN
Alvotech and Dr. Reddy’s to co-develop biosimilar to Keytruda - World Pharmaceutical Frontiers
Dr Reddy’s shares climb over 4% after Keytruda biosimilar deal with Alvotech - MSN
Alvotech to Participate in Goldman Sachs 46th Global Healthcare Conference in Miami - Nasdaq
Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami - Yahoo
Alvotech (ALVO) Trading Down 4.8% on Jun 4 - GuruFocus
Alvotech Completes SEK 750 Million Private Placement to Boost R&D and Market Position - TipRanks
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug - Benzinga
Alvotech Stock (ALVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.94%
2.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):